Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
FORA vs INFU vs JPM vs BAC vs BRT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Banks - Diversified
Banks - Diversified
REIT - Residential
FORA vs INFU vs JPM vs BAC vs BRT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Instruments & Supplies | Banks - Diversified | Banks - Diversified | REIT - Residential |
| Market Cap | $68M | $190M | $908.57B | $424.14B | $280M |
| Revenue (TTM) | $30M | $142M | $280.33B | $191.57B | $98M |
| Net Income (TTM) | $-5M | $8M | $57.05B | $30.51B | $-12M |
| Gross Margin | 46.8% | 56.7% | 60.0% | 56.1% | 41.5% |
| Operating Margin | -13.4% | 9.1% | 25.9% | 19.7% | 12.4% |
| Forward P/E | — | 22.2x | 14.6x | 12.6x | — |
| Total Debt | $12K | $3M | $942.38B | $365.90B | $508M |
| Cash & Equiv. | $13M | $3M | $343.34B | $231.84B | $25M |
FORA vs INFU vs JPM vs BAC vs BRT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Forian Inc. (FORA) | 100 | 21.5 | -78.5% |
| InfuSystem Holdings… (INFU) | 100 | 49.8 | -50.2% |
| JPMorgan Chase & Co. (JPM) | 100 | 205.8 | +105.8% |
| Bank of America Cor… (BAC) | 100 | 138.2 | +38.2% |
| BRT Apartments Corp. (BRT) | 100 | 85.3 | -14.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FORA vs INFU vs JPM vs BAC vs BRT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FORA has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 50.1%, EPS growth 23.0%, 3Y rev CAGR 22.6%
- Lower volatility, beta 0.21, Low D/E 0.0%, current ratio 2.97x
- 50.1% revenue growth vs BAC's -0.5%
- Beta 0.21 vs INFU's 1.22, lower leverage
INFU is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +52.2% vs BRT's -0.2%
- 7.9% ROA vs FORA's -11.8%, ROIC 12.5% vs -7.5%
JPM ranks third and is worth considering specifically for long-term compounding and bank quality.
- 481.2% 10Y total return vs BAC's 371.6%
- NIM 2.2% vs BAC's 1.8%
- 20.4% margin vs FORA's -17.0%
- 1.8% yield, 15-year raise streak, vs BRT's 7.0%, (2 stocks pay no dividend)
BAC is the clearest fit if your priority is valuation efficiency.
- PEG 0.82 vs JPM's 0.83
- Better valuation composite
BRT is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 0.45, yield 7.0%
- Beta 0.45, yield 7.0%, current ratio 0.86x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 50.1% revenue growth vs BAC's -0.5% | |
| Value | Better valuation composite | |
| Quality / Margins | 20.4% margin vs FORA's -17.0% | |
| Stability / Safety | Beta 0.21 vs INFU's 1.22, lower leverage | |
| Dividends | 1.8% yield, 15-year raise streak, vs BRT's 7.0%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +52.2% vs BRT's -0.2% | |
| Efficiency (ROA) | 7.9% ROA vs FORA's -11.8%, ROIC 12.5% vs -7.5% |
FORA vs INFU vs JPM vs BAC vs BRT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FORA vs INFU vs JPM vs BAC vs BRT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
INFU leads 2 • FORA leads 0 • BAC leads 0 • BRT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 9328.3x FORA's $30M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to FORA's -17.0%. On growth, BRT holds the edge at +4.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $30M | $142M | $280.3B | $191.6B | $98M |
| EBITDAEarnings before interest/tax | -$4M | $26M | $81.4B | $40.0B | $39M |
| Net IncomeAfter-tax profit | -$5M | $8M | $57.0B | $30.5B | -$12M |
| Free Cash FlowCash after capex | $2M | $20M | $100.9B | $12.6B | $12M |
| Gross MarginGross profit ÷ Revenue | +46.8% | +56.7% | +60.0% | +56.1% | +41.5% |
| Operating MarginEBIT ÷ Revenue | -13.4% | +9.1% | +25.9% | +19.7% | +12.4% |
| Net MarginNet income ÷ Revenue | -17.0% | +5.6% | +20.4% | +15.9% | -12.5% |
| FCF MarginFCF ÷ Revenue | +7.8% | +14.3% | +36.0% | +6.6% | +12.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.9% | -3.0% | — | — | +4.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.0% | +5.9% | +16.0% | +18.3% | -16.7% |
Valuation Metrics
INFU leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 14.7x trailing earnings, BAC trades at a 52% valuation discount to INFU's 30.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs BAC's 0.96x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $68M | $190M | $908.6B | $424.1B | $280M |
| Enterprise ValueMkt cap + debt − cash | $55M | $190M | $1.51T | $558.2B | $763M |
| Trailing P/EPrice ÷ TTM EPS | -23.48x | 30.39x | 16.22x | 14.71x | -22.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.16x | 14.60x | 12.60x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.92x | 0.96x | — |
| EV / EBITDAEnterprise value multiple | — | 7.55x | 18.52x | 13.95x | 20.41x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 1.33x | 3.25x | 2.21x | 2.89x |
| Price / BookPrice ÷ Book value/share | 2.27x | 3.47x | 2.51x | 1.40x | 1.51x |
| Price / FCFMarket cap ÷ FCF | 23.49x | 7.97x | 9.01x | 33.63x | 42.18x |
Profitability & Efficiency
INFU leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-17 for FORA. FORA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BRT's 2.87x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs BRT's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.2% | +14.0% | +15.9% | +10.1% | -6.8% |
| ROA (TTM)Return on assets | -11.8% | +7.9% | +1.3% | +0.9% | -1.7% |
| ROICReturn on invested capital | -7.5% | +12.5% | +4.5% | +3.5% | +1.3% |
| ROCEReturn on capital employed | -8.2% | +14.3% | +8.9% | +4.5% | +1.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 5 | 7 | 3 |
| Debt / EquityFinancial leverage | 0.00x | 0.06x | 2.60x | 1.21x | 2.87x |
| Net DebtTotal debt minus cash | -$13M | $241,000 | $599.0B | $134.1B | $483M |
| Cash & Equiv.Liquid assets | $13M | $3M | $343.3B | $231.8B | $25M |
| Total DebtShort + long-term debt | $12,137 | $3M | $942.4B | $365.9B | $508M |
| Interest CoverageEBIT ÷ Interest expense | -48.78x | 15.54x | 0.74x | 0.48x | 0.51x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $1,735 for FORA. Over the past 12 months, INFU leads with a +52.2% total return vs BRT's -0.2%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs BRT's -3.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.4% | +12.3% | +0.8% | +1.4% | +4.7% |
| 1-Year ReturnPast 12 months | +2.4% | +52.2% | +20.9% | +27.2% | -0.2% |
| 3-Year ReturnCumulative with dividends | -7.3% | -7.6% | +138.8% | +105.5% | -11.2% |
| 5-Year ReturnCumulative with dividends | -82.7% | -50.2% | +135.5% | +57.4% | +13.1% |
| 10-Year ReturnCumulative with dividends | -90.5% | +240.1% | +481.2% | +371.6% | +221.6% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -2.6% | +33.7% | +27.1% | -3.9% |
Risk & Volatility
Evenly matched — FORA and BAC each lead in 1 of 2 comparable metrics.
Risk & Volatility
FORA is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than INFU's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 96.9% from its 52-week high vs FORA's 80.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.21x | 1.22x | 0.87x | 0.83x | 0.45x |
| 52-Week HighHighest price in past year | $2.71 | $11.04 | $338.09 | $57.98 | $16.69 |
| 52-Week LowLowest price in past year | $1.64 | $5.38 | $269.72 | $44.21 | $13.18 |
| % of 52W HighCurrent price vs 52-week peak | +80.1% | +85.3% | +96.2% | +96.9% | +89.2% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 41.5 | 72.1 | 70.9 | 52.6 |
| Avg Volume (50D)Average daily shares traded | 40K | 172K | 7.4M | 32.4M | 32K |
Analyst Outlook
Evenly matched — JPM and BRT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: INFU as "Buy", JPM as "Buy", BAC as "Buy", BRT as "Buy". Consensus price targets imply 59.2% upside for INFU (target: $15) vs 4.5% for JPM (target: $340). For income investors, BRT offers the higher dividend yield at 7.05% vs JPM's 1.83%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $15.00 | $339.75 | $61.13 | $21.00 |
| # AnalystsCovering analysts | — | 3 | 61 | 54 | 5 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.8% | +2.3% | +7.0% |
| Dividend StreakConsecutive years of raises | — | — | 15 | 12 | 0 |
| Dividend / ShareAnnual DPS | — | — | $5.95 | $1.27 | $1.05 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +5.8% | +3.8% | +5.1% | +1.8% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). INFU leads in 2 (Valuation Metrics, Profitability & Efficiency). 2 tied.
FORA vs INFU vs JPM vs BAC vs BRT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FORA or INFU or JPM or BAC or BRT a better buy right now?
For growth investors, Forian Inc.
(FORA) is the stronger pick with 50. 1% revenue growth year-over-year, versus -0. 5% for Bank of America Corporation (BAC). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FORA or INFU or JPM or BAC or BRT?
On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.
7x versus InfuSystem Holdings, Inc. at 30. 4x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 82x versus JPMorgan Chase & Co. 's 0. 83x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FORA or INFU or JPM or BAC or BRT?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -82. 7% for Forian Inc. (FORA). Over 10 years, the gap is even starker: JPM returned +481. 2% versus FORA's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FORA or INFU or JPM or BAC or BRT?
By beta (market sensitivity over 5 years), Forian Inc.
(FORA) is the lower-risk stock at 0. 21β versus InfuSystem Holdings, Inc. 's 1. 22β — meaning INFU is approximately 480% more volatile than FORA relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 3% for BRT Apartments Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — FORA or INFU or JPM or BAC or BRT?
By revenue growth (latest reported year), Forian Inc.
(FORA) is pulling ahead at 50. 1% versus -0. 5% for Bank of America Corporation (BAC). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -26. 9% for BRT Apartments Corp.. Over a 3-year CAGR, FORA leads at 22. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FORA or INFU or JPM or BAC or BRT?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -12. 3% for BRT Apartments Corp. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -8. 2% for FORA. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FORA or INFU or JPM or BAC or BRT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 82x versus JPMorgan Chase & Co. 's 0. 83x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 22. 2x for InfuSystem Holdings, Inc. — 9. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INFU: 59. 2% to $15. 00.
08Which pays a better dividend — FORA or INFU or JPM or BAC or BRT?
In this comparison, BRT (7.
0% yield), BAC (2. 3% yield), JPM (1. 8% yield) pay a dividend. FORA, INFU do not pay a meaningful dividend and should not be held primarily for income.
09Is FORA or INFU or JPM or BAC or BRT better for a retirement portfolio?
For long-horizon retirement investors, BRT Apartments Corp.
(BRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 7. 0% yield, +221. 6% 10Y return). Both have compounded well over 10 years (BRT: +221. 6%, INFU: +240. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FORA and INFU and JPM and BAC and BRT?
These companies operate in different sectors (FORA (Healthcare) and INFU (Healthcare) and JPM (Financial Services) and BAC (Financial Services) and BRT (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FORA is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; BRT is a small-cap income-oriented stock. JPM, BAC, BRT pay a dividend while FORA, INFU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.